Amp Volatility Score
Catalyst Info & Data Links
TITLE: Peginterferon Lambda-1a in COVID-19 - Phase 1
ClinicalTrial.gov (NCT04331899): Single-Blind Study of a Single Dose of Peginterferon Lambda-1a Compared With Placebo in Outpatients With Mild COVID-19 (COVID-Lambda)
WHAT IS THE NEXT CATALYST EVENT?
WHEN WILL THE EVENT (OR DID THE EVENT) OCCUR?
09-2020: Corporate Presentation (slides: 26 - 28)
MECHANISM OF ACTION / RATIONALE
Lambda is a well-characterized, late-stage, first in class, type Ill interferon (IFN) that stimulates immune responses critical for the development of host protection during viral infections. Lambda targets type III IFN receptors which are distinct from the type I IFN receptors targeted by IFN alfa. These type III receptors are highly expressed on hepatocytes with limited expression on hematopoietic and central nervous system cells, which may reduce off-target effects and improve tolerability of lambda. Although Lambda does not use the IFN alfa receptor, signaling through either the IFN lambda or IFN alfa receptor complexes results in the activation of the same Jak-STAT signal transduction cascade (learn more).
Updated by HC
#EIGR, #Interferon, #Lambda, #COVID
Prior Data (click to view full image)
Trial Design / Revenue (click to view full image)
See What The Community Is Saying - Click To See Full Post